Association of high sensitivity C-reactive protein and metabolic syndrome components in middle-aged subjects without overt cardiovascular disease in LitHiR primary prevention programme

[1] Wang J, Tan G-J, Han L-N, Bai Y-Y, He M, Liu H-B. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol JGC 2017;14(2):135–50.Search in Google Scholar

[2] Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367(14):1310–20.10.1056/NEJMoa1107477371410123034020Search in Google Scholar

[3] Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis 2017;259:75–82.10.1016/j.atherosclerosis.2017.02.00328327451Search in Google Scholar

[4] Shah PK, Lecis D. Inflammation in atherosclerotic cardiovascular disease. F1000Res 2019;8:F1000 Faculty Rev-1402.10.12688/f1000research.18901.1669444731448091Search in Google Scholar

[5] Wu M-Y, Li C-J, Hou M-F, Chu P-Y. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci 2017;18(10):2034.10.3390/ijms18102034566671628937652Search in Google Scholar

[6] Ridker PM. A Test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol 2016;67(6):712–23.10.1016/j.jacc.2015.11.03726868696Search in Google Scholar

[7] Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, Mc-Cabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20–8.10.1056/NEJMoa04237815635109Search in Google Scholar

[8] Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836–43.10.1056/NEJM20000323342120210733371Search in Google Scholar

[9] Wang A, Liu J, Li C, Gao J, Li X, Chen S, et al. Cumulative exposure to high-sensitivity C-reactive protein predicts the risk of cardiovascular disease. J Am Heart Assoc 2017;6(10):e005610.10.1161/JAHA.117.005610572182429066453Search in Google Scholar

[10] Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109(23):2818–25.10.1161/01.CIR.0000132467.45278.5915197153Search in Google Scholar

[11] Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol 2017;960:1–17.10.1007/978-3-319-48382-5_128585193Search in Google Scholar

[12] Laucevičius A, Rinkūnienė E, Skujaitė A, Petrulionienė Ž, Puronaitė R, Dženkevičiūtė V, et al. Prevalence of cardiovascular risk factors in Lithuanian middle-aged subjects participating in the primary prevention program, analysis of the period 2009–2012. Blood Press 2015;24(1):41–7.10.3109/08037051.2014.96174425268930Search in Google Scholar

[13] Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107(3):391–7.10.1161/01.CIR.0000055014.62083.05Search in Google Scholar

[14] Sigdel M, Kumar A, Gyawali P, Shrestha R, Tuladhar ET, Jha B. Association of high sensitivity C-reactive protein with the components of metabolic syndrome in diabetic and non-diabetic individuals. J Clin Diagn Res JCDR. 2014;8(6):CC11–3.10.7860/JCDR/2014/8085.4522412930425120975Search in Google Scholar

[15] Abu-Farha M, Behbehani K, Elkum N. Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs. Cardiovasc Diabetol 2014;13:76.10.1186/1475-2840-13-76399723624716628Search in Google Scholar

[16] Laucevičius, A.; Kasiulevičius, V.; Jatužis, D.; Petrulionienė, Ž.; Ryliškytė, L.; Rinkūnienė, E. et al, Lithuanian High Cardiovascular Risk (LitHiR) primary prevention programme-rationale and design. Semin Cardiovasc Med:2012;18:3–6.10.2478/v10287-012-0003-3Search in Google Scholar

[17] Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 2001;285(19):2486–97.10.1001/jama.285.19.248611368702Search in Google Scholar

[18] Voils SA, Cooper-DeHoff RM. Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009–10. Diabetes Metab Syndr 2014;8(2):88–90.10.1016/j.dsx.2014.04.02124907172Search in Google Scholar

[19] Mirhafez SR, Ebrahimi M, Saberi Karimian M, Avan A, Tayefi M, Heidari-Bakavoli A, et al. Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects. Eur J Clin Nutr 2016;70(11):1298–304.10.1038/ejcn.2016.11127460263Search in Google Scholar

[20] Mazidi M, Toth PP, Banach M. C-reactive protein is associated with prevalence of the metabolic syndrome, hypertension, and diabetes mellitus in US adults. Angiology 2018;69(5):438–42.10.1177/000331971772928828914081Search in Google Scholar

[21] den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salomé PL, Rutten GE. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol 2012;11:25.10.1186/1475-2840-11-25335923622417460Search in Google Scholar

[22] Belfki H, Ben Ali S, Bougatef S, Ben Ahmed D, Haddad N, Jmal A, et al. Relationship of C-reactive protein with components of the metabolic syndrome in a Tunisian population. Eur J Intern Med. 2012;23(1):e5–9.10.1016/j.ejim.2011.10.01122153549Search in Google Scholar

[23] Hoekstra T, Geleijnse JM, Schouten EG, Kok FJ, Kluft C. Relationship of C-reactive protein with components of the metabolic syndrome in normal-weight and overweight elderly. Nutr Metab Cardiovasc Dis 2005;15(4):270–8.10.1016/j.numecd.2005.01.00416054551Search in Google Scholar

[24] Garcia VP, Rocha HN, Sales ARK, Rocha NG, Nobrega ACL. Sex Differences in high sensitivity C-reactive protein in subjects with risk factors of metabolic syndrome. Arq Bras Cardiol 2016;106(3):182–7.10.5935/abc.20160027481127227027366Search in Google Scholar

[25] Song Y, Yang SK, Kim J, Lee D-C. Association between C-reactive protein and metabolic syndrome in Korean adults. Korean J Fam Med 2019;40(2):116–23.10.4082/kjfm.17.0075644409030373358Search in Google Scholar

[26] Kianoush S, Yakoob MY, Al-Rifai M, DeFilippis AP, Bittencourt MS, Duncan BB, et al. Associations of cigarette smoking with subclinical inflammation and atherosclerosis: ELSA-Brasil (The Brazilian longitudinal study of adult health). J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2016;6(6):e005088.10.1161/JAHA.116.005088566915628647689Search in Google Scholar

[27] Jamal O, Aneni EC, Shaharyar S, Ali SS, Parris D, McEvoy JW, et al. Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome. Diabetol Metab Syndr 2014;6(1):79.10.1186/1758-5996-6-79442479125960769Search in Google Scholar

[28] Kazemi-Bajestani SM, Tayefi M, Ebrahimi M, Heidari-Bakavoli AR, Moohebati M, Parizadeh SM, et al. The prevalence of metabolic syndrome increases with serum high sensitivity C-reactive protein concentration in individuals without a history of cardiovascular disease: a report from a large Persian cohort. Ann Clin Biochem 2017;54(6):644–8.10.1177/000456321667684227742849Search in Google Scholar